Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
112.39
+0.50 (0.45%)
At close: Apr 3, 2025, 4:00 PM
111.31
-1.08 (-0.96%)
Pre-market: Apr 4, 2025, 9:25 AM EDT
Gilead Sciences Revenue
In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth. Gilead Sciences had revenue of $7.57B in the quarter ending December 31, 2024, with 6.40% growth.
Revenue (ttm)
$28.75B
Revenue Growth
+6.04%
P/S Ratio
4.87
Revenue / Employee
$1,633,750
Employees
17,600
Market Cap
139.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GILD News
- 7 hours ago - Top 3 Nasdaq 100 stocks rising as it moves into a correction - Invezz
- 2 days ago - Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks - CNBC
- 5 days ago - Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025) - Seeking Alpha
- 7 days ago - Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. - Market Watch
- 11 days ago - Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha
- 16 days ago - Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barrons
- 23 days ago - Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - Business Wire
- 23 days ago - Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript) - Seeking Alpha